IBIO
Price
$0.59
Change
-$0.00 (-0.00%)
Updated
Aug 11, 04:59 PM (EDT)
Capitalization
9.64M
REPL
Price
$4.99
Change
-$0.49 (-8.94%)
Updated
Aug 11, 04:59 PM (EDT)
Capitalization
412.92M
99 days until earnings call
Interact to see
Advertisement

IBIO vs REPL

Header iconIBIO vs REPL Comparison
Open Charts IBIO vs REPLBanner chart's image
iBio
Price$0.59
Change-$0.00 (-0.00%)
Volume$135
Capitalization9.64M
Replimune Group
Price$4.99
Change-$0.49 (-8.94%)
Volume$49.63K
Capitalization412.92M
IBIO vs REPL Comparison Chart in %
Loading...
IBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IBIO vs. REPL commentary
Aug 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IBIO is a Hold and REPL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 12, 2025
Stock price -- (IBIO: $0.59 vs. REPL: $5.48)
Brand notoriety: IBIO and REPL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IBIO: 17% vs. REPL: 0%
Market capitalization -- IBIO: $9.48M vs. REPL: $389.5M
IBIO [@Biotechnology] is valued at $9.48M. REPL’s [@Biotechnology] market capitalization is $389.5M. The market cap for tickers in the [@Biotechnology] industry ranges from $96.01B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IBIO’s FA Score shows that 1 FA rating(s) are green whileREPL’s FA Score has 1 green FA rating(s).

  • IBIO’s FA Score: 1 green, 4 red.
  • REPL’s FA Score: 1 green, 4 red.
According to our system of comparison, both IBIO and REPL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IBIO’s TA Score shows that 4 TA indicator(s) are bullish while REPL’s TA Score has 5 bullish TA indicator(s).

  • IBIO’s TA Score: 4 bullish, 4 bearish.
  • REPL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, REPL is a better buy in the short-term than IBIO.

Price Growth

IBIO (@Biotechnology) experienced а -9.83% price change this week, while REPL (@Biotechnology) price change was -27.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +22.22%. For the same industry, the average monthly price growth was +31.78%, and the average quarterly price growth was +19.63%.

Reported Earning Dates

REPL is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+22.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REPL($413M) has a higher market cap than IBIO($9.64M). REPL YTD gains are higher at: -54.748 vs. IBIO (-75.747). IBIO has higher annual earnings (EBITDA): -15.11M vs. REPL (-235.43M). REPL has more cash in the bank: 484M vs. IBIO (4.96M). IBIO has less debt than REPL: IBIO (3.76M) vs REPL (76.2M). IBIO has higher revenues than REPL: IBIO (375K) vs REPL (0).
IBIOREPLIBIO / REPL
Capitalization9.64M413M2%
EBITDA-15.11M-235.43M6%
Gain YTD-75.747-54.748138%
P/E Ratio0.65N/A-
Revenue375K0-
Total Cash4.96M484M1%
Total Debt3.76M76.2M5%
FUNDAMENTALS RATINGS
IBIO vs REPL: Fundamental Ratings
IBIO
REPL
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
19
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
9596
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
n/a5

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REPL's Valuation (19) in the Biotechnology industry is in the same range as IBIO (21). This means that REPL’s stock grew similarly to IBIO’s over the last 12 months.

REPL's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as IBIO (100). This means that REPL’s stock grew similarly to IBIO’s over the last 12 months.

REPL's SMR Rating (98) in the Biotechnology industry is in the same range as IBIO (99). This means that REPL’s stock grew similarly to IBIO’s over the last 12 months.

IBIO's Price Growth Rating (95) in the Biotechnology industry is in the same range as REPL (96). This means that IBIO’s stock grew similarly to REPL’s over the last 12 months.

IBIO's P/E Growth Rating (98) in the Biotechnology industry is in the same range as REPL (100). This means that IBIO’s stock grew similarly to REPL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IBIOREPL
RSI
ODDS (%)
Bullish Trend 4 days ago
89%
Bullish Trend 4 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
77%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
83%
MACD
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
86%
Advances
ODDS (%)
Bullish Trend 20 days ago
79%
Bullish Trend 13 days ago
78%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
76%
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
IBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CTM1.280.06
+4.92%
Castellum
BAP249.203.20
+1.30%
Credicorp Ltd
INHD1.21N/A
-0.08%
Inno Holdings Inc
CVLG23.11-0.28
-1.20%
Covenant Logistics Group Inc
IAC34.17-0.56
-1.60%
IAC

IBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBIO has been loosely correlated with REPL. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if IBIO jumps, then REPL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBIO
1D Price
Change %
IBIO100%
-0.13%
REPL - IBIO
38%
Loosely correlated
N/A
LIANY - IBIO
37%
Loosely correlated
N/A
NUVB - IBIO
36%
Loosely correlated
-1.71%
LENZ - IBIO
35%
Loosely correlated
+7.97%
STOK - IBIO
31%
Poorly correlated
-1.13%
More

REPL and

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with IMNN. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then IMNN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
N/A
IMNN - REPL
56%
Loosely correlated
-12.60%
SNDX - REPL
49%
Loosely correlated
-1.89%
KYMR - REPL
46%
Loosely correlated
-0.56%
ERAS - REPL
44%
Loosely correlated
-4.11%
BEAM - REPL
43%
Loosely correlated
-1.34%
More